Table 2.
Detailed characteristics of patients with inflammatory bowel disease (IBD).
| Ulcerative Colitis (UC) Patients Visits, Total Samples |
n (%) 53 69 |
Crohn’s Disease (CD) Patients Visits, Total Samples |
n (%) 97 143 |
|
|---|---|---|---|---|
| Age diagnosis | A1 (<17 years) A2 (17–40 years) A3 (>40 years) |
2 (4) 36 (68) 15 (28) |
A1 (<17 years) A2 (17–40 years) A3 (>40 years) Not documented |
13 (13) 68 (70) 14 (14) 2 (2) |
| Localization | E1 (proctitis) E2 (left-sided colitis) E3 (pancolitis) |
1 (2) 24 (45) 28 (55) |
L1 (ileal) L2 (colonic) L3 (ileocolonic) L4* (+ upper GI disease) L4 (isolated upper GI dis.) Not documented |
35 (36) 15 (16) 44 (45) 27 (28) 1 (1) 2 (2) |
| Behavior | P (perianal disease) Previous surgery1 |
9 (17) 1 (2) |
B1 (inflammatory) B2 (stricturing) B3 (penetrating) p (perianal disease) Previous surgery1 |
54 (55) 24 (24) 20 (20) 39 (40) 31 (32) |
| Disease duration years (mean ± SD) |
9.7 ± 8.2 |
53 |
12.3 ± 10.5 |
95 |
| Smoking status | Never Former Current |
23 (43) 27 (51) 3 (6) |
Never Former Current |
43 (44) 26 (27) 28 (29) |
| Family history | IBD negative IBD positive Unknown |
39 (74) 11 (21) 3 (6) |
IBD negative IBD positive Unknown |
75 (77) 19 (20) 3 (3) |
| Clinical activity Missing: n = 19 |
Inactive (SCCAI ≤ 2) Mild (SCCAI 3–5) Moderate (SCCAI 6–10) Severe (SCCAI ≥ 11) |
28 (44) 19 (30) 15 (23) 2 (3) |
Inactive (HBI ≤ 4) Mild (HBI 5–7) Moderate (HBI 8–16) Severe (HBI ≥ 17) |
74 (57) 22 (17) 31 (24) 2 (2) |
| Endoscopic activity Not performed: n = 129 |
Inactive (Mayo = 0) Mild (Mayo = 1) Moderate (Mayo = 2) Severe (Mayo = 3) |
3 (7) 12 (29) 14 (34) 12 (29) |
Inactive (SES-CD 0–2) Mild (SES-CD 3–6) Moderate (SES-CD 7–15) Severe (SES-CD ≥ 16) |
14 (33) 8 (19) 14 (33) 6 (14) |
| Medication Missing: n = 0 |
5-ASA 2 Steroids 3 Steroids (>10 mg 4) Thiopurins Methotrexat Anti-TNF 5 Vedolizumab Tacrolimus Antibiotics/Virostatics Probiotics |
63 (92) 27 (39) 13 (19) 19 (28) 1 (1) 21 (30) 0 (0) 2 (3) 3 (4) 1 (1) |
5-ASA 2
Steroids 3 Steroids (>10 mg 4) Thiopurins Methotrexat Anti-TNF Vedolizumab Tacrolimus Antibiotics/Virostatics Probiotics |
40 (28) 32 (22) 11 (8) 34 (24) 1 (1) 56 (39) 1 (1) 1 (1) 7 (5) 0 (0) |
| CRP (mg/dL) Median (IQR) ≥5 mg/dL |
2.1 (0.9–6.9) |
68 25 (37) |
2.3 (0.7–5.9) |
140 39 (28) |
* patients with L1/ L2 or L3, combined with L4 (upper GI disease), 1 IBD-related surgery without perianal surgery, 2 including topical 5-aminosalicylic acid (ASA), 3 budesonide and topical steroids, 4 prednisolon/prednison equivalent, and 5 tumor necrosis factor (TNF). CRP: C-reactive protein; HBI: Harvey-Bradshaw Index; SCCAI: Simple Clinical Colitis Activity Index; SES-CD: Simple Endoscopic Score for CD.